Adherex Technologies’ (FENC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Adherex Technologies (NASDAQ:FENC) in a research note released on Wednesday morning,Benzinga reports. They currently have a $16.00 target price on the stock. HC Wainwright also issued estimates for Adherex Technologies’ Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.09 EPS, FY2026 earnings at $0.21 EPS, Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.19 EPS and FY2027 earnings at $0.87 EPS.

Several other equities analysts have also recently weighed in on FENC. Wall Street Zen raised Adherex Technologies from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Friday, July 17th. Zacks Research upgraded shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Wedbush raised their target price on Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, B. Riley Financial restated a “buy” rating and set a $18.00 price objective (up from $16.00) on shares of Adherex Technologies in a research report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Adherex Technologies Price Performance

FENC stock opened at $10.96 on Wednesday. The company has a fifty day moving average price of $11.11 and a two-hundred day moving average price of $9.16. The stock has a market cap of $384.26 million, a price-to-earnings ratio of -84.31 and a beta of 1.10. Adherex Technologies has a one year low of $5.65 and a one year high of $13.25.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Adherex Technologies had a negative return on equity of 5.71% and a negative net margin of 6.09%.The company had revenue of $17.87 million during the quarter, compared to analysts’ expectations of $16.21 million. Research analysts anticipate that Adherex Technologies will post 0.28 EPS for the current fiscal year.

Insider Transactions at Adherex Technologies

In other Adherex Technologies news, insider Pierre Sargis Sayad sold 12,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the sale, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. The trade was a 55.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Robert Andrade sold 75,000 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the completion of the sale, the chief financial officer directly owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.73% of the company’s stock.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC purchased a new position in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.